证券代码：835670 证券简称：数字人 公告编号：2023-007 山东数字人科技股份有限公司 持股 5%以上股东减持股份结果公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担个别及连带法律责任。 | 减持价 | 减 | 当前持 | | | | | | | | | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 格区间 | 持 | 股数量 | | | | | | | | | | | | | | | | | | | 股 | 减 | 减 | 计 | （股） | 已减持 | 已减 | 当前 | | | | | | | | | | | | | | 东 | 持 | 持 | 已减持总金 | 划 | 数量 | 持 | 持股 | | | | | | | | | | | | | | 名 | 方 | 期 | ...

信息披露义务人：东源华信（北京）资本管理有限公司 法定代表人：孙境新 住所：北京市朝阳区西大望路27号[2-1]79幢一层D11 权益变动性质：股份减少 1 证券代码：835670 证券简称：数字人 公告编号：2023-006 山东数字人科技股份有限公司 简式权益变动报告书 信息披露义务人及其主要负责人保证公告内容的真实、准确和完整，不存在虚假记 载、误导性陈述或者重大遗漏。 信息披露义务人保证除本报告书披露的信息外，没有通过任何其他方式增加或减少其 在上市公司所拥有权益的股份。 第一节 释义 在本报告书中，除非文义载明，以下简称具有如下含义： | 上市公司、公司、数字人 | 指 | 山东数字人科技股份有限公司 | | --- | --- | --- | | 信息披露义务人、东源华信 | 指 | 东源华信（北京）资本管理有限公司 | | 报告书、本报告书 | 指 | 《山东数字人科技股份有限公司简式权益变动报告书》 | | 证监会 | 指 | 中国证券监督管理委员会 | | 北交所、证券交易所 | 指 | 北京证券交易所 | | 本次权益变动 | 指 | 信息披露义务人通过集中竞价交易和大宗交易方式减 持，导 ...

Financial Performance - The company's operating revenue for 2022 was ¥71,427,286.01, a decrease of 14.68% compared to the previous year[3]. - The net profit attributable to shareholders was -¥4,917,142.60, representing a decline of 130.85% year-on-year[5]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥6,468,948.24, down 155.83% from the previous year[5]. - Basic earnings per share were -¥0.05, a decrease of 120.83% compared to the same period last year[5]. Assets and Equity - Total assets at the end of the reporting period were ¥270,747,844.76, an increase of 2.12% year-on-year[5]. - Shareholders' equity attributable to the company was ¥239,628,155.22, down 5.84% from the previous year[5]. - The number of shares increased to 106,182,400, reflecting a growth of 60% during the reporting period[5]. - The net asset value per share attributable to shareholders was ¥2.26, a decrease of 40.99% year-on-year[5]. Operational Challenges - The decline in net profit was primarily due to project delays caused by pandemic policies, resulting in approximately ¥45 million in unimplemented orders by the end of 2022[6]. - Increased R&D investment to accelerate new product launches contributed to the decline in net profit[6].

Financial Performance - The company expects a net profit attributable to shareholders of approximately -4.9171 million yuan for the year 2022, compared to a profit of 15.9398 million yuan in the same period last year[2] - The decline in net profit is primarily due to project delays caused by pandemic policies, with around 45 million yuan in related orders not implemented by the end of 2022[4] R&D Investment - Increased R&D investment to accelerate new product launches has led to higher expenses, contributing to the overall loss[4]

证券代码：835670 证券简称：数字人 公告编号：2023-003 山东数字人科技股份有限公司 关于持股 5%以上股东减持公司股份超过 1%的提示性公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 一、 本次权益变动基本情况 （一） 信息披露义务人基本情况 1、基本情况 | 信息披露义务人 | | 东源华信（北京）资本管理有限公司 | | | --- | --- | --- | --- | | 持股变动时间 | 2023 年 1 | 月 30 日-2023 年 2 月 | 1 日 | | 股票简称 | 数字人 | 股票代码 | 835670 | | 变动类型 | 增加□ 减少√ | 一致行动人 | 有□ 无√ | | 是否为第一大股东或实际 控制人 | | 是□ 否√ | | | 2、本次权益变动情况 | | | | | 股东名称 | 变动方式 | 减持股数（股） | 减持比例 | | 东源华信（北京）资本管 | 集中竞价 | 55,000 | 0.05% | | 理有限公司－华信扬帆 1 号投资 ...

证券代码：835670 证券简称：数字人 公告编号：2023-002 山东数字人科技股份有限公司 持股 5%以上股东减持股份进展公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、 减持主体减持前基本情况 | 股东名称 | 股东身份 | | 持股数量（股） | 持股比例 | 当前持股股份来源 | | --- | --- | --- | --- | --- | --- | | 东源华信（北京） | 持股 | 5%以 | 4,339,200 | 4.0866% | 公开发行前取得 | | 资本管理有限公 | 上股东 | | | | （含权益分派转增 | | 司－华信扬帆1号 | | | | | 股） | | 投资基金 | | | | | | | 东源华信（北京） | 持股 | 5%以 | 3,664,000 | 3.4507% | 公 开 发 行 前 取 得 | | 资本管理有限公 | 上股东 | | | | （含权益分派转增 | | 司－济南源之信 | | | | | 股） | | 股权投资基金合 ...

证券代码：835670 证券简称：数字人 公告编号：2023-001 山东数字人科技股份有限公司 关于持股 5%以上股东减持公司股份超过 1%的提示性公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 一、 本次权益变动基本情况 （一） 信息披露义务人基本情况 | 1.基本情况 | | | | | | --- | --- | --- | --- | --- | | 信息披露义务人 | | 东源华信（北京）资本管理有限公司 | | | | 持股变动时间 | 年 2022 | 月 日-2023 年 11 21 | 月 日 1 6 | | | 股票简称 | 数字人 | 股票代码 | | 835670 | | 变动类型 | 增加□ 减少√ | 一致行动人 | | 有□ 无√ | | 是否为第一大股东或实 际控制人 | | 是□ 否√ | | | | 2、本次权益变动情况 | | | | | | 股东名称 | 变动方式 | 减持股数（股） | | 减持比例 | | 东源华信（北京）资本 | 集中竞价 | 3,2 ...

证券代码：835670 证券简称：数字人 公告编号：2022-091 山东数字人科技股份有限公司 关于接待机构投资者调研情况的公告 | --- | |--------------------------------------------------------------------| | | | 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假 | | 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 | | 担个别及连带法律责任。 | 山东数字人科技股份有限公司（以下简称"公司"）于 2022 年 11 月 9 日 接待了 5 家机构的调研，现将主要情况公告如下： 一、 调研情况 调研时间：2022 年 11 月 9 日 调研地点：山东数字人科技股份有限公司会议室 调研形式：现场调研 调研机构：山东弘阳信基金管理有限公司、上海临彤资产管理有限公司、青 岛稳泰私募基金管理有限公司、安信证券股份有限公司、银河证券股份有限公司 上市公司接待人员：董事长徐以发先生 董事、副总经理、董事会秘书李相 东先生 二、 调研的主要问题及公司回复概要 问题 1、请问近期疫情对公司业务开展的影 ...

Financial Performance - The company's operating revenue for the current period is 7,145,928.19, a decrease of 68.10% compared to the same period last year, which was 22,398,249.14 [30]. - The net profit attributable to shareholders of the listed company is -14,147,839.48, representing a decline of 1,418.07% from -931,963.54 in the previous year [30]. - The total assets at the end of the current period amount to 239,733,083.38, down 9.58% from 265,127,970.96 at the end of the previous year [31]. - The net cash flow from operating activities is -15,037,521.56, a significant decline of 2,580.07% compared to -561,087.22 in the same period last year [32]. - The company's gross profit margin increased to 66.90% from 57.70% year-on-year [30]. - The company reported a significant increase in credit impairment losses, with a loss of -99,200.39 in the first half of 2022 compared to a gain of 1,282,363.48 in the same period of 2021 [158]. - The company reported a total comprehensive loss of CNY 14,441,748.73, compared to -931,963.54 in the first half of 2021 [159]. Research and Development - The company's R&D expenses for the first half of 2022 amounted to 11.92 million CNY, representing 166.82% of its operating revenue [14]. - The company has established two parallel R&D departments: the R&D Center and the Digital Human Research Institute, focusing on core technologies such as image acquisition and data processing [47]. - The company is focused on continuous technological innovation and product upgrades to meet evolving customer demands [14]. - The company has developed a 3D printed embryo model, which can be used in conjunction with its "Digital Embryo" system for teaching and demonstration [39]. - The company is committed to enhancing product quality and increasing R&D investment to maintain competitive advantages in technology and customer satisfaction [95]. Market and Competition - The company faces risks related to changes in industry policies that could adversely affect its operations if supportive measures are withdrawn [13]. - The company is exposed to market competition risks as the medical informationization industry accelerates, potentially impacting revenue growth [13]. - The demand for medical education products is expected to grow due to the aging population and increased government investment in medical education [46]. - The company is focusing on expanding its sales channels and enhancing its sales team to mitigate the impact of seasonal revenue fluctuations [88]. - The company is actively monitoring industry policy changes to adapt its strategies accordingly [87]. Corporate Governance - The company has established a complete corporate governance structure since its transformation into a joint-stock company in August 2015 [15]. - The actual controller, Xu Yifa, directly and indirectly controls 41.71% of the company's shares [15]. - The governance structure is being further standardized to ensure compliance with legal regulations and protect minority shareholders' interests [96]. - The company has committed to maintaining fair and equivalent compensation principles in related transactions [101]. - The company is focused on maintaining compliance with corporate governance standards to protect the interests of all shareholders [107]. Financial Management - The company distributed a cash dividend of 1.50 CNY per 10 shares and increased capital reserves by issuing 6 additional shares for every 10 shares held [8]. - The total amount of tax benefits and government subsidies received during the reporting period was 2.58 million yuan, which is a significant portion of the company's profits [15]. - The company has invested a total of RMB 85 million in various financial products, with no overdue amounts or expected impairments [74]. - The company approved the use of up to RMB 30 million of idle raised funds for purchasing low-risk financial products, with a decision valid for one year [75]. - The company has a commitment to ensure that any business dealings are conducted fairly and equitably [101]. Operational Challenges - The company acknowledges the potential adverse impact of the COVID-19 pandemic on its operations, particularly affecting client procurement plans [14]. - The company is committed to enhancing its internal control and risk prevention systems to ensure long-term stable development [50]. - The company has identified risks related to the loss of core technical personnel, which could adversely affect its R&D capabilities and operational performance [92]. - The company is actively enhancing its quality control systems to prevent product quality issues that could harm its market reputation [89]. - The company is at risk of adverse impacts on net profit if there are unfavorable changes to tax incentive policies related to the software industry [94]. Shareholder Information - The company has a total share capital of 106,182,400 shares [23]. - The largest shareholder, Xu Yifa, holds 40.85% of the shares, with a total of 43,378,037 shares after an increase of 16,266,764 shares during the reporting period [117]. - The total number of shareholders holding more than 5% of shares or among the top ten shareholders is 64,619,407, accounting for 60.86% of total shares [117]. - The company has not reported any breaches of commitments by its major shareholders or executives during the reporting period [106]. - The company has ongoing commitments to compensate investors for any losses incurred due to misleading information in securities transactions [102].

Financial Performance - The company's operating revenue for the current period is ¥7,145,928.19, a decrease of 68.10% compared to the same period last year, which was ¥22,398,249.14[30]. - The net profit attributable to shareholders of the listed company is -¥14,147,839.48, representing a decline of 1418.07% from -¥931,963.54 in the previous year[30]. - The total assets at the end of the current period amount to ¥239,733,083.38, down 9.58% from ¥265,127,970.96 at the end of the previous year[31]. - The company reported a net cash flow from operating activities of -¥15,037,521.56, a significant decline of 2580.07% compared to -¥561,087.22 in the previous year[32]. - The company's total comprehensive income for the first half of 2022 was -13,414,181.01, compared to -404,604.67 in the same period of 2021[163]. - The company incurred a comprehensive loss of -14,147,839.48 during the first half of 2022, contributing to the decline in total equity[171]. Research and Development - R&D expenses for the first half of 2022 amounted to 11.92 million CNY, representing 166.82% of the operating revenue[14]. - The company has developed over 100 digital medical education products, indicating a strong focus on research and development in the digital medicine sector[38]. - The company has established two parallel R&D departments: the R&D Center and the Digital Human Research Institute, focusing on core technologies such as image acquisition and data processing[47]. - The company emphasizes talent development and aims to establish a competitive compensation structure to attract and retain skilled personnel[49]. - The company has recognized the risk of technology innovation and is committed to timely updates and product upgrades to maintain its competitive edge[91]. Market and Competition - The company is exposed to market competition risks as the medical informationization industry accelerates, potentially impacting revenue growth[13]. - The company is positioned to benefit from the growing demand for medical education products due to ongoing reforms and increased government investment in medical education[46]. - The company plans to expand its overseas medical education market in alignment with the "Belt and Road" initiative, seizing historical development opportunities[49]. - The company is actively monitoring industry policy changes that could impact its operations, with a focus on adapting to new regulations[88]. Corporate Governance and Structure - The company has established a sound corporate governance structure since its transformation into a joint-stock company in August 2015[15]. - The actual controller of the company, Xu Yifa, directly and indirectly controls 41.71% of the shares[15]. - The company has committed to avoiding related party transactions and has adhered to this commitment without any violations during the reporting period[107]. - The board of directors and management team consists of 9 members, with a mix of experienced professionals in key positions[132]. Financial Management - The company received a total of 2.58 million yuan in government subsidies and tax benefits, which is a significant portion of its profit[15]. - The company has invested a total of RMB 85 million in various financial products, with no overdue amounts or expected impairments[75]. - The company reported a total investment income of RMB 140,506.85 from low-risk financial products during the first half of 2022[127]. - The company has not experienced any significant changes in the feasibility of its fundraising projects[127]. Risks and Challenges - The company faces risks related to changes in industry policies that could adversely affect operations if supportive measures are withdrawn[13]. - The company acknowledges the potential adverse impact of the COVID-19 pandemic on its operations, particularly affecting client procurement plans[13]. - There is a risk that changes in tax policies could adversely affect the company's future net profits[15]. - The company has faced substantial impacts on business expansion and implementation due to repeated COVID-19 outbreaks, affecting overall performance[61]. Shareholder Information - The total share capital of the company is 106,182,400 shares, with no preferred shares issued[23]. - The total number of unrestricted shares increased from 32,485,227 (48.95%) to 53,528,363 (50.41%) during the reporting period[114]. - The total number of restricted shares decreased from 33,878,773 (51.05%) to 52,654,037 (49.59%) during the reporting period[114]. - The company has maintained a performance guarantee deposit of 340,780.00 yuan, representing 0.14% of total assets, with no adverse impact on operations[111]. Product Development and Innovation - The "Digital Human Anatomy System" and "Medical Morphology Digital Teaching Platform" are key products aimed at improving teaching quality and efficiency in medical education[38]. - The company is developing personalized clinical data analysis systems and virtual surgical training systems to meet clinical needs[55]. - The company has formed partnerships with numerous medical universities since 2014, enhancing its R&D capabilities in high-precision digital human products[48]. - The company emphasizes brand building through technical and brand marketing, participating in exhibitions to increase product visibility[48].